To enhance industry-academia cooperation, National Defense Medical University (NDMU), the Pharmaceutical Industry Technology Development Center (hereafter referred to as PITDC), and Johnson Chemical Pharmaceutical Works Co., Ltd. (hereafter referred to as JCP) officially signed an academic-research cooperation agreement on Friday, June 5. This signing ceremony highlights the close collaboration among the three institutions in the field of "Critical Pharmaceutical Platform Technology Development," jointly marching towards a new era for our nation's pharmaceutical industry.
Cooperation Objectives
"Continuous Manufacturing Training Pharmacy"
"Hot-Melt Extrusion Pilot Plant"
▲ (From left) Chairman Tzu-Ting Fan of PITDC, President Chih-Yuan Lin of NDMU, and Chairman Po-Hsiung Huang of JCP jointly displaying the cooperation agreement.
✨ Combining Industry Advantages to Implement Domestic Pharmaceutical Manufacturing
The professional team at PITDC has long been dedicated to pharmaceutical process technology and industry counseling, possessing outstanding practical experience in promoting PIC/S GMP certification for pharmaceuticals and the internationalization of the domestic pharmaceutical industry. JCP is deeply engaged in the R&D and manufacturing of solid dosage forms, equipped with diverse technologies such as tablets, capsules, and powders, and continues to introduce advanced hot-melt extrusion processes. Through this powerful trilateral alliance, we can not only further elevate the professional skills of our nation's pharmaceutical development but also align with the government's promotion of "Pharmaceutical Resilience Defense." Moving towards "Domestic Pharmaceutical Manufacturing" effectively fulfills our university's core mission of continuously advancing industrial pharmacy and "strengthening the military and protecting the nation."
▲ President Chih-Yuan Lin and Chairman Tzu-Ting Fan of PITDC signing the agreement.
▲ President Chih-Yuan Lin and Chairman Po-Hsiung Huang of JCP signing the agreement.
✨ Focusing on Four Core Dimensions to Lead Pharmaceutical Upgrades
The signing ceremony was grandly held at NDMU. PITDC was represented by Chairman Tzu-Ting Fan and General Manager Pei-Yu Wang; JCP was represented by Chairman Po-Hsiung Huang and General Manager Hao-Hsi Su. NDMU was represented by President Chih-Yuan Lin, Director Li-Min Lin, Director Chia-Fu Hsu, and Dean Hung-Chan Wang of the School of Pharmacy, along with other colleagues.
Facing the challenges of AI application upgrades and domestic and international regulations, the substantive collaboration of the three parties will focus on four core dimensions:
(1) Actively promoting critical technology development
(2) Jointly implementing pilot production research
(3) Designing innovative practical training courses
(4) Optimizing drug development and accelerating technology transfer to GMP plants
Thereby comprehensively enhancing quality control and ultimately ensuring the health and well-being of patients.
▲ Group photo of the PITDC team and NDMU faculty.
▲ Group photo of the JCP team and NDMU faculty.
▲ In-depth discussion and exchange between representatives prior to signing.
▲ Official signing of the academic-research cooperation agreement.
This collaboration is expected to unlock a series of opportunities for innovation and progress. By establishing a domestically advanced process practice and teaching platform, we will not only strengthen the practical capabilities of our students but also propel Taiwan's overall pharmaceutical industry towards a higher level of international competitiveness.